315 related articles for article (PubMed ID: 19407318)
1. Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Gaymes TJ; Shall S; MacPherson LJ; Twine NA; Lea NC; Farzaneh F; Mufti GJ
Haematologica; 2009 May; 94(5):638-46. PubMed ID: 19407318
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.
Jasek E; Gajda M; Lis GJ; Jasińska M; Litwin JA
Anticancer Res; 2014 Apr; 34(4):1849-56. PubMed ID: 24692719
[TBL] [Abstract][Full Text] [Related]
4. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
5. Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Piao J; Takai S; Kamiya T; Inukai T; Sugita K; Ohyashiki K; Delia D; Masutani M; Mizutani S; Takagi M
Cancer Lett; 2017 Feb; 386():131-140. PubMed ID: 27894958
[TBL] [Abstract][Full Text] [Related]
6. Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies.
Gaymes TJ; Mohamedali AM; Patterson M; Matto N; Smith A; Kulasekararaj A; Chelliah R; Curtin N; Farzaneh F; Shall S; Mufti GJ
Haematologica; 2013 Sep; 98(9):1397-406. PubMed ID: 23349304
[TBL] [Abstract][Full Text] [Related]
7. PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Xiong T; Wei H; Chen X; Xiao H
Int J Oncol; 2015 Jan; 46(1):223-32. PubMed ID: 25351371
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab ozogamicin and olaparib exert synergistic cytotoxicity in CD33-positive HL-60 myeloid leukemia cells.
Yamauchi T; Uzui K; Nishi R; Shigemi H; Ueda T
Anticancer Res; 2014 Oct; 34(10):5487-94. PubMed ID: 25275045
[TBL] [Abstract][Full Text] [Related]
9. The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2'-deoxycytidine lesions.
Orta ML; Höglund A; Calderón-Montaño JM; Domínguez I; Burgos-Morón E; Visnes T; Pastor N; Ström C; López-lázaro M; Helleday T
Nucleic Acids Res; 2014 Aug; 42(14):9108-20. PubMed ID: 25074383
[TBL] [Abstract][Full Text] [Related]
10. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2'-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells.
Shaker S; Bernstein M; Momparler LF; Momparler RL
Leuk Res; 2003 May; 27(5):437-44. PubMed ID: 12620295
[TBL] [Abstract][Full Text] [Related]
11. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
Esposito MT; Zhao L; Fung TK; Rane JK; Wilson A; Martin N; Gil J; Leung AY; Ashworth A; So CW
Nat Med; 2015 Dec; 21(12):1481-90. PubMed ID: 26594843
[TBL] [Abstract][Full Text] [Related]
12. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
13. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Wang M; Wu W; Wu W; Rosidi B; Zhang L; Wang H; Iliakis G
Nucleic Acids Res; 2006; 34(21):6170-82. PubMed ID: 17088286
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of anticancer drugs and PJ-34 (poly(ADP-ribose)polymerase-1 (PARP-1) inhibitor) on HL-60 and Jurkat cells.
Stępnik M; Spryszyńska S; Gorzkiewicz A; Ferlińska M
Adv Clin Exp Med; 2017; 26(3):379-385. PubMed ID: 28791810
[TBL] [Abstract][Full Text] [Related]
15. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
[TBL] [Abstract][Full Text] [Related]
16. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Wiltshire TD; Lovejoy CA; Wang T; Xia F; O'Connor MJ; Cortez D
J Biol Chem; 2010 May; 285(19):14565-71. PubMed ID: 20233726
[TBL] [Abstract][Full Text] [Related]
18. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Goodyear O; Agathanggelou A; Novitzky-Basso I; Siddique S; McSkeane T; Ryan G; Vyas P; Cavenagh J; Stankovic T; Moss P; Craddock C
Blood; 2010 Sep; 116(11):1908-18. PubMed ID: 20530795
[TBL] [Abstract][Full Text] [Related]
19. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
20. Roles of inhibitors of poly(ADP-ribose) polymerase in protecting rat RINm5F cell line against free fatty acid-induced apoptosis.
Mao X; Wang S; Pan Y; He B; Chen J; Jiang H; Zeng Q; Xu X
Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):274-82. PubMed ID: 19513971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
